Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CADL Candel Therapeutics	$5.53 -5.5%	$5.19	$3.79 ▼ $14.60	$277.07M	-0.92	1.45 million shs	1.10 million shs
GOSS Gossamer Bio	$1.12 -1.3%	$1.00	$0.50 ▼ $1.55	$253.44M	1.82	1.54 million shs	1.08 million shs
OCGN Ocugen	$0.84 +1.2%	$0.73	$0.52 ▼ $1.98	$246.56M	4.21	4.47 million shs	2.94 million shs
VTGN Vistagen Therapeutics	$2.52 -1.2%	$2.31	$1.90 ▼ $4.21	$74.46M	0.67	171,148 shs	92,202 shs

10 Stocks Set to Soar in Spring 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CADL Candel Therapeutics	0.00%	+1.84%	+4.73%	-30.09%	-37.87%
GOSS Gossamer Bio	0.00%	-7.08%	-5.51%	-5.51%	+88.98%
OCGN Ocugen	0.00%	-9.29%	+10.37%	+39.53%	-51.20%
VTGN Vistagen Therapeutics	0.00%	+4.56%	+5.88%	+1.20%	-34.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CADL Candel Therapeutics	1.9791 of 5 stars	3.5	1.0	0.0	2.5	1.7	0.6
GOSS Gossamer Bio	4.0203 of 5 stars	3.5	2.0	4.7	3.5	1.7	0.0
OCGN Ocugen	1.1307 of 5 stars	3.5	0.0	0.0	2.8	0.0	0.0
VTGN Vistagen Therapeutics	1.5378 of 5 stars	0.0	3.0	0.0	3.5	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CADL Candel Therapeutics	3.00	Buy	$21.00	279.75% Upside
GOSS Gossamer Bio	3.00	Buy	$7.75	595.07% Upside
OCGN Ocugen	3.00	Buy	$6.00	610.65% Upside
VTGN Vistagen Therapeutics	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest VTGN, GOSS, CADL, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/17/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
4/11/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/18/2025	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/14/2025	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/14/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
3/6/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$6.00 ➝ $7.00
3/6/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CADL Candel Therapeutics	$120K	2,308.91	N/A	N/A	$0.44 per share	12.57
GOSS Gossamer Bio	$124.59M	2.03	N/A	N/A	$0.28 per share	3.98
OCGN Ocugen	$4.52M	54.52	N/A	N/A	$0.16 per share	5.28
VTGN Vistagen Therapeutics	$698K	104.20	N/A	N/A	$2.81 per share	0.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CADL Candel Therapeutics	-$37.94M	-$1.34	N/A	N/A	N/A	N/A	-629.29%	-173.39%	8/12/2025 (Estimated)
GOSS Gossamer Bio	-$179.82M	-$0.23	N/A	N/A	N/A	N/A	-127.28%	-22.12%	8/11/2025 (Estimated)
OCGN Ocugen	-$63.08M	-$0.19	N/A	N/A	N/A	-532.51%	-154.75%	-90.79%	8/14/2025 (Estimated)
VTGN Vistagen Therapeutics	-$29.36M	-$1.48	N/A	N/A	N/A	-6,777.08%	-48.12%	-43.80%	6/10/2025 (Estimated)

Latest VTGN, GOSS, CADL, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/10/2025	Q4 2025	VTGN Vistagen Therapeutics	-$0.53	N/A	N/A	N/A	$0.18 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/13/2025	Q1 2025	CADL Candel Therapeutics	-$0.24	$0.13	+$0.37	$0.13	N/A	N/A
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
3/18/2025	Q4 2024	GOSS Gossamer Bio	-$0.15	-$0.15	N/A	-$0.15	$7.02 million	$9.38 million
3/13/2025	Q4 2024	CADL Candel Therapeutics	-$0.23	-$0.40	-$0.17	-$0.40	N/A	N/A
3/5/2025	Q4 2024	OCGN Ocugen	-$0.05	-$0.05	N/A	-$0.05	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
VTGN Vistagen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CADL Candel Therapeutics	N/A	1.18	1.18
GOSS Gossamer Bio	3.64	6.74	6.74
OCGN Ocugen	0.04	2.58	2.58
VTGN Vistagen Therapeutics	N/A	9.35	9.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CADL Candel Therapeutics	13.93%
GOSS Gossamer Bio	81.23%
OCGN Ocugen	10.27%
VTGN Vistagen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
CADL Candel Therapeutics	16.60%
GOSS Gossamer Bio	6.70%
OCGN Ocugen	4.42%
VTGN Vistagen Therapeutics	1.29%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CADL Candel Therapeutics	60	50.10 million	18.97 million	Optionable
GOSS Gossamer Bio	180	227.30 million	215.27 million	Optionable
OCGN Ocugen	80	292.03 million	278.82 million	Optionable
VTGN Vistagen Therapeutics	40	28.86 million	28.49 million	Optionable

VTGN, GOSS, CADL, and OCGN Headlines

Recent News About These Companies

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above 50 Day Moving Average - Should You Sell?

May 28, 2025 | marketbeat.com

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Above Fifty Day Moving Average - Time to Sell?

May 27, 2025 | americanbankingnews.com

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

May 23, 2025 | businesswire.com

Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

May 8, 2025 | marketbeat.com

Almitas Capital LLC Purchases New Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)

May 4, 2025 | marketbeat.com

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

April 17, 2025 | businesswire.com

Why Vistagen Therapeutics, Inc.’s (VTGN) Stock Is Down 10.10%

April 8, 2025 | aaii.com

VistaGen at Stifel 2025: Pioneering Acute SAD Treatment

March 20, 2025 | investing.com

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

March 19, 2025 | businesswire.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript

February 15, 2025 | msn.com

VistaGen’s Earnings Call: Progress and Challenges

February 14, 2025 | tipranks.com

Vistagen: Pherine Candidate Proof Of Concept Continues With Fifth Indication

February 14, 2025 | seekingalpha.com

StemPoint Capital LP's Strategic Acquisition of Vistagen Therapeutics Inc Shares

February 14, 2025 | gurufocus.com

Vistagen Therapeutics Inc (VTGN) Q3 2025 Earnings Call Highlights: Promising Trial Results and ...

February 14, 2025 | gurufocus.com

Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript

February 14, 2025 | gurufocus.com

Vistagen advances Phase 3 SAD trials with 2025 data readout target

February 13, 2025 | msn.com

Vistagen reports Q3 EPS (46c) vs (22c) last year

February 13, 2025 | markets.businessinsider.com

Earnings call transcript: VistaGen Therapeutics reports Q3 FY2025 net loss

February 13, 2025 | msn.com

Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call Transcript

February 13, 2025 | seekingalpha.com

VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates

February 13, 2025 | zacks.com

Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. ...

February 13, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VTGN, GOSS, CADL, and OCGN Company Descriptions

Candel Therapeutics NASDAQ:CADL

$5.53 -0.32 (-5.47%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$5.45 -0.08 (-1.45%)

As of 08:09 AM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Gossamer Bio NASDAQ:GOSS

$1.12 -0.02 (-1.33%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.13 +0.01 (+1.35%)

As of 08:24 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Ocugen NASDAQ:OCGN

$0.84 +0.01 (+1.21%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.85 +0.00 (+0.20%)

As of 08:36 AM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Vistagen Therapeutics NASDAQ:VTGN

$2.52 -0.03 (-1.18%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$2.62 +0.10 (+3.77%)

As of 08:36 AM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time